BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market.
Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions. The unmet need is in the delivery of these agents via a more convenient, and improved vehicle. Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category. For parents, this product is designed to be a potentially better and easier to use product."
Cooper Collins, Pernix Therapeutics' President and CEO, said, "We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email firstname.lastname@example.org contact us at (610) 861-4701 for information.
Contact: Maureen Mattera, (610) 861-4701, email@example.com
SOURCE Particle Sciences, Inc.